PEN · Penumbra, Inc.
Price
Snapshot
50 fields · last close| Market Cap | $12.71B |
| P/E | 79.35 |
| Float | 38.26M |
| Beta | 0.65 |
| Volatility 30D | 8.8% |
| Exchange | NYSE |
| Sector | Health Care |
| Cap tier | Large cap |
| Macro sensitivity | Moderate |
| Clavix score | 92.9 |
| Price | 320.52 |
| Change | −0.60% |
| Prev Close | 322.45 |
| Open | 324.30 |
| Day Low | 322.20 |
| Day High | 324.38 |
| Avg Vol | 0 |
| Avg $ Vol | $160.0M |
| 52W High | 362.41 |
| 52W Low | 221.26 |
| 52W Pos | 70.3% |
| From High | −11.56% |
| From Low | +44.86% |
| Max DD 1Y | −12.23% |
| Spread | 0.10% |
| Liquidity | Normal |
| SMA 20 | −0.34% |
| SMA 50 | +0.06% |
| SMA 200 | −1.99% |
| RSI (14) | 53.1 |
| Vol 90D | 7.3% |
| Vol 1Y | 25.7% |
| 1Y Range | 221–362 |
| Daily bars | 549 |
| Perf Week | +1.30% |
| Perf Month | +1.70% |
| Perf Quarter | −0.74% |
| Perf Half Y | −0.54% |
| Perf Year | +42.56% |
| Perf YTD | +3.59% |
| Prev Day | −0.60% |
| Clavix | A+ |
| Debt / Eq | 0.02 |
| Curr Ratio | 6.64 |
| Int Cover | — |
| FCF Margin | 12.5% |
| Rev Growth | +17.5% |
| Profit | Profitable |
| Leverage | Low |
| Sector rank | 1 / 49 |
Clavix risk grade
regraded every trading dayPEN grades A+, 92.9 of 100. Steadiest on Price Stability (78), most exposed on News Sentiment (67, steady). 4 of the 4 weighted dimensions sit above the Health Care median. Ranks 1 of 49 in Health Care by Clavix score.
How rough the ride is
| PEN | Health Care median | |
|---|---|---|
| Betavs the overall market · lower is steadier | 0.65 | 0.79 |
| 30-day realized volatilityannualized, from daily closes | 8.8% | 36.1% |
| Max drawdown, past yearworst peak-to-trough fall | −12.2% | — |
| Typical daily movemedian absolute daily change | 0.33% | — |
| Days beyond ±3%of the last 252 sessions | 12 (5%) | — |
How its days are spread
Daily returns over the last 252 sessions in 1% bins. Moves beyond ±6% land in the end bins.
52-week range
The bar runs from the lowest to the highest close of the last 252 sessions; the marker is the latest close.
Drawdown from the 1-year peak
Percent below the running high over the last 12 months. Zero is a fresh high.
Market sensitivity
| PEN | Health Care median | |
|---|---|---|
| Beta to the markethow much it swings with the S&P 500 · lower is safer | 0.65 | 0.79 |
| Macro sensitivityrate, dollar and credit exposure bucket | Moderate | Moderate 51% of 49 |
Where it sits on the macro scale
Low means rates, the dollar and credit spreads barely move it. Very High means they drive a large share of its swings. The counts are how many Health Care names sit in each bucket.
Where it ranks in its sector
Rank by Clavix score within the sector. Right is the top of the sector.
Price performance
| PEN | |
|---|---|
| 1 week | +1.3% |
| 1 month | +1.7% |
| Year to date | +3.6% |
| 1 year | +42.6% |
Context for the rank, not itself a risk measure.
Recent coverage, scored
| PEN | |
|---|---|
| Articles scoredthe most recent scored coverage, up to 30 | 17 since 18 Jun |
| Average score0 most bearish, 100 most bullish | 59 |
| Bullish · bearisharticles above 60 · below 40 | 10 · 4 |
| Directionarticles whose tone is improving vs worsening | 10 ↑ 4 ↓ |
Where the article scores land
Each bar is a 10-point band of article scores. Below 40 reads bearish, above 60 bullish.
Balance sheet, against the sector
The shaded band is the middle half of the 49 Health Care names Clavix covers; the tick is the sector median.
Growth
| PEN | |
|---|---|
| Revenue growthyear over year | +17.5% |
Financial Health is shown but does not count toward the grade. Why
0–100, higher is safer. The tick on each bar is the Health Care median. Click a dimension for the evidence behind it. Financial Health is shown but does not count toward the grade.
Recent news
most recent scored articles · the chip is the article’s score · click to openPenumbra reported Q3 2026 revenue of $410.1 million, with 18.1% growth in thrombectomy, a procedure used to remove blood clots, helping lift sales. Earnings were $1.07 per share, below the $1.25 estimate.
Penumbra reported third-quarter 2026 revenue of $410.1 million, up 15.6%, for the period ended September 30, 2026. The provided article excerpt is truncated and does not include earnings, margins, cash flow, guidance, or operational details.
Penumbra reported third-quarter 2026 revenue of $410.1 million, up 15.6% from a year earlier, with gross profit margin of 68.3%, operating income of $50.7 million and net income of $42.3 million. The company did not provide full-year guidance or host an earnings call because of its pending acquisition by Boston Scientific.
Washington Trust Advisors Inc. reduced its holdings in Penumbra (NYSE: PEN) by 22.7% in the third quarter, according to its latest disclosure with the SEC. The firm sold 1,743 shares and ended the period with 5,928 Penumbra shares.
A Reddit user is betting against Penumbra (PEN) by buying put options because they believe the announced $374-per-share buyout by Boston Scientific will fail. The post cites the FTC issuing a 'Second Request' for additional information on March 16, 2026, signaling deeper antitrust scrutiny of the deal.
Nearest peers by size
Health Care| Ticker | Company | Grade | Mkt cap | P/E | Beta | |
|---|---|---|---|---|---|---|
| COO | The Cooper Companies, Inc. | B | $12.25B | 20.28 | 0.79 | Compare |
| DVA | DaVita Inc | B | $12.12B | 12.75 | 0.82 | Compare |
| MOH | Molina Healthcare Inc | B | $11.82B | 22.99 | 0.69 | Compare |
| BAX | Baxter International Inc. | B | $13.71B | — | 0.62 | Compare |
| ALGN | Align Technology, Inc. | B | $11.71B | 27.75 | 1.72 | Compare |
| GMED | Globus Medical, Inc. | B+ | $11.69B | 19.96 | 0.93 | Compare |
| BTSG | Brightspring Health Services Inc | B | $13.89B | 37.97 | 1.79 | Compare |
| PODD | Insulet Corporation | B- | $11.44B | 28.61 | 1.08 | Compare |
You just read one holding. Clavix reads the whole portfolio.
Every position you own, graded on the same five dimensions, with an alert when a grade moves. 1 month free on iPhone.